Literature DB >> 27250490

[IL-2-Therapy in SLE- Selective reconstitution of immunological tolerance].

J Y Humrich1, G Riemekasten2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27250490     DOI： 10.1007/s00393-016-0129-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  12 in total

1.  Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.

Authors:  Jens Y Humrich; Caroline von Spee-Mayer; Elise Siegert; Tobias Alexander; Falk Hiepe; Andreas Radbruch; Gerd-Rüdiger Burmester; Gabriela Riemekasten
Journal:  Ann Rheum Dis       Date:  2015-01-21       Impact factor: 19.103

2.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.

Authors:  David Saadoun; Michelle Rosenzwajg; Florence Joly; Adrien Six; Fabrice Carrat; Vincent Thibault; Damien Sene; Patrice Cacoub; David Klatzmann
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

3.  Interleukin-2 and regulatory T cells in graft-versus-host disease.

Authors:  John Koreth; Ken-ichi Matsuoka; Haesook T Kim; Sean M McDonough; Bhavjot Bindra; Edwin P Alyea; Philippe Armand; Corey Cutler; Vincent T Ho; Nathaniel S Treister; Don C Bienfang; Sashank Prasad; Dmitrios Tzachanis; Robin M Joyce; David E Avigan; Joseph H Antin; Jerome Ritz; Robert J Soiffer
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

4.  A function for interleukin 2 in Foxp3-expressing regulatory T cells.

Authors:  Jason D Fontenot; Jeffrey P Rasmussen; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2005-10-16       Impact factor: 25.606

5.  Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus.

Authors:  Jens Y Humrich; Henner Morbach; Reinmar Undeutsch; Philipp Enghard; Stefan Rosenberger; Olivia Weigert; Lutz Kloke; Juliane Heimann; Timo Gaber; Susan Brandenburg; Alexander Scheffold; Jochen Huehn; Andreas Radbruch; Gerd-Rüdiger Burmester; Gabriela Riemekasten
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

Review 6.  [Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance].

Authors:  K Ohl; K Tenbrock
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

7.  Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.

Authors:  Caroline von Spee-Mayer; Elise Siegert; Dimas Abdirama; Angelika Rose; Anika Klaus; Tobias Alexander; Philipp Enghard; Birgit Sawitzki; Falk Hiepe; Andreas Radbruch; Gerd-Rüdiger Burmester; Gabriela Riemekasten; Jens Y Humrich
Journal:  Ann Rheum Dis       Date:  2015-08-31       Impact factor: 19.103

Review 8.  The biology of interleukin-2.

Authors:  Thomas R Malek
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

Review 9.  Interleukin-2 and systemic lupus erythematosus--fifteen years later.

Authors:  J C Crispin; J Alcocer-Varela
Journal:  Lupus       Date:  1998       Impact factor: 2.911

10.  Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Authors:  S Alice Long; Mary Rieck; Srinath Sanda; Jennifer B Bollyky; Peter L Samuels; Robin Goland; Andrew Ahmann; Alex Rabinovitch; Sudeepta Aggarwal; Deborah Phippard; Laurence A Turka; Mario R Ehlers; Peter J Bianchine; Karen D Boyle; Steven A Adah; Jeffrey A Bluestone; Jane H Buckner; Carla J Greenbaum
Journal:  Diabetes       Date:  2012-06-20       Impact factor: 9.461
View more
  1 in total

Review 1.  [Pathogenesis of systemic lupus erythematosus].

Authors:  S Finzel; S Schaffer; M Rizzi; R E Voll
Journal:  Z Rheumatol       Date:  2018-11       Impact factor: 1.372
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.